Literature DB >> 35710755

Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains.

Khloe S Gordon1,2,3, Taeyoon Kyung1,2, Caleb R Perez1,2, Patrick V Holec1,2, Azucena Ramos1,4, Angela Q Zhang1,5, Yash Agarwal1,2, Yunpeng Liu1,4, Catherine E Koch1,4, Alina Starchenko2, Brian A Joughin1,2, Douglas A Lauffenburger2,6, Darrell J Irvine1,2,6, Michael T Hemann1,4, Michael E Birnbaum7,8,9,10.   

Abstract

The immunostimulatory intracellular domains (ICDs) of chimaeric antigen receptors (CARs) are essential for converting antigen recognition into antitumoural function. Although there are many possible combinations of ICDs, almost all current CARs rely on combinations of CD3𝛇, CD28 and 4-1BB. Here we show that a barcoded library of 700,000 unique CD19-specific CARs with diverse ICDs cloned into lentiviral vectors and transduced into Jurkat T cells can be screened at high throughput via cell sorting and next-generation sequencing to optimize CAR signalling for antitumoural functions. By using this screening approach, we identified CARs with new ICD combinations that, compared with clinically available CARs, endowed human primary T cells with comparable tumour control in mice and with improved proliferation, persistence, exhaustion and cytotoxicity after tumour rechallenge in vitro. The screening strategy can be adapted to other disease models, cell types and selection conditions, and could be used to improve adoptive cell therapies and to expand their utility to new disease indications.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35710755      PMCID: PMC9389442          DOI: 10.1038/s41551-022-00896-0

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   29.234


  56 in total

Review 1.  Jurkat T cells and development of the T-cell receptor signalling paradigm.

Authors:  Robert T Abraham; Arthur Weiss
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

2.  Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.

Authors:  Andreas A Hombach; Hinrich Abken
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

Review 3.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

4.  A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity.

Authors:  Huihui Zhang; Fanlin Li; Jiang Cao; Xin Wang; Hai Cheng; Kunming Qi; Gang Wang; Kailin Xu; Junnian Zheng; Yang-Xin Fu; Xuanming Yang
Journal:  Sci Transl Med       Date:  2021-01-27       Impact factor: 17.956

Review 5.  Chimeric antigen receptor T-cell therapy for solid tumors.

Authors:  Kheng Newick; Edmund Moon; Steven M Albelda
Journal:  Mol Ther Oncolytics       Date:  2016-04-13       Impact factor: 7.200

Review 6.  CAR-T cells: the long and winding road to solid tumors.

Authors:  Maria Michela D'Aloia; Ilaria Grazia Zizzari; Benedetto Sacchetti; Luca Pierelli; Maurizio Alimandi
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

Review 7.  Chimeric antigen receptor signaling: Functional consequences and design implications.

Authors:  S E Lindner; S M Johnson; C E Brown; L D Wang
Journal:  Sci Adv       Date:  2020-05-20       Impact factor: 14.136

8.  Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells.

Authors:  Rebekah R Bartelt; Noemi Cruz-Orcutt; Michaela Collins; Jon C D Houtman
Journal:  PLoS One       Date:  2009-05-04       Impact factor: 3.240

9.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Authors:  Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; John P Ray; Carl G de Boer; Russell W Jenkins; David J Lieb; Jonathan H Chen; Dennie T Frederick; Michal Barzily-Rokni; Samuel S Freeman; Alexandre Reuben; Paul J Hoover; Alexandra-Chloé Villani; Elena Ivanova; Andrew Portell; Patrick H Lizotte; Amir R Aref; Jean-Pierre Eliane; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Bo Li; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Zachary A Cooper; Cloud P Paweletz; David A Barbie; Anat Stemmer-Rachamimov; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

10.  MyD88/CD40 signaling retains CAR T cells in a less differentiated state.

Authors:  Brooke Prinzing; Patrick Schreiner; Matthew Bell; Yiping Fan; Giedre Krenciute; Stephen Gottschalk
Journal:  JCI Insight       Date:  2020-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.